Fig. 1 · Structure

Documents & Downloads

Emtricitabine

Cat. No. A10349 CAS 143491-57-0

NRT inhibitor

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Emtricitabine’s active 5′-triphosphate is incorporated by HIV-1 reverse transcriptase. Purified-enzyme experiments also showed poor incorporation by human mitochondrial polymerase γ, with strong stereoisomer dependence. These metabolite kinetics do not establish parent-drug cellular potency or a clinical toxicity advantage. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HIV-1  
HIV-2  

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM CC50 > 100 μM Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days [PMID: 32515595]
CCRF-CEM EC50 0.04 μM Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days [PMID: 26878150]
HeLa EC50 > 404 μM Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay [PMID: 22352809]
HeLa EC50 0.8 μM Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay [PMID: 22352809]
HeLa EC50 2 μM Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay [PMID: 22352809]
HepG2 ED50 17 nM Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line [PMID: 8627596]
HepG2 IC50 27.7 μM Cytotoxicity against human HepG2 cells after 9 days by MTT assay [PMID: 17888662]
HepG2 ED50 30 nM Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line [PMID: 8627596]
HepG2 CC50 765 μM Cytotoxicity against human HepG2 cells after 3 days by MTT assay [PMID: 17404006]
HepG2 2.2.15 EC50 0.1 μM Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR [PMID: 17404006]
HL-60 CC50 845 μM Cytotoxicity against human HL60 cells after 3 days by MTT assay [PMID: 17404006]
MT2 EC50 323 nM Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS [PMID: 19104010]
PBMC CC50 > 10 μM Cytotoxicity against human PBMC cells assessed as cell viability measured after 11 days by Viacount assay [PMID: 34795872]

13 records · Scroll to view more

Emtricitabine Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Emtricitabine from 2 published references.

Emtricitabine In Vitro Studies

In primary lymphoid endothelial cells, emtricitabine exposure produced measurable intracellular FTC-TP but ranked in the low-bioavailability tertile of the tested panel. The endpoint normalized intracellular triphosphate to extracellular parent drug; it was not an antiviral inhibition assay. [2]

Active-metabolite incorporation by HIV-1 reverse transcriptase

Biochemical assay · Purified recombinant HIV-1 RT; synthetic DNA–DNA primer–template [1]

The active triphosphate was incorporated during DNA-dependent synthesis. This endpoint measures enzyme kinetics, not parent-drug cellular potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DNA-dependent nucleotide incorporationkpol 0.039 ± 0.003 s−1 (mean ± standard error)[1]
DNA-dependent incorporation efficiencykpol/Kd 0.0033 μM−1 s−1[1]

Literature-Reported Treatment Conditions

Treatment concentration
Variable (−)FTC-TP concentrations; not a parent-drug dose
Method
Pre-steady-state rapid-quench incorporation analysis at 37°C
Reported limits
No single treatment concentration or fixed exposure duration applies; replicate count not specified for Table 3.
Methods and source locations

Compound reported in the paper: Emtricitabine 5′-triphosphate; Compound label in the paper: (−)FTC-TP

Mechanistic metabolite evidence; supplied parent emtricitabine was not assayed directly.

Table 3, DNA–DNA columns and footnotes; Materials and Methods: Reagents and rapid chemical quenching

DNA-dependent nucleotide incorporation: Transient kinetic analysis — Table 3: (−)FTC-TP row, DNA–DNA kpol; footnote a

DNA-dependent incorporation efficiency: Reported ratio of kinetic parameters — Table 3: (−)FTC-TP row, DNA–DNA kpol/Kd

Stereoselective incorporation by human mitochondrial polymerase γ

Biochemical assay · Recombinant human mitochondrial DNA polymerase γ holoenzyme; synthetic DNA–DNA substrate [1]

The (−) triphosphate was a much poorer substrate than the (+) enantiomer. Biochemical discrimination alone does not establish comparative clinical toxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maximum observed (−)FTC-TP incorporation ratekpol (8.6 ± 1.5) × 10−3 s−1 (mean ± standard error)[1]
Incorporation efficiencies of FTC enantiomerskpol/Kd (−)FTC-TP: 1.4 × 10−4; (+)FTC-TP: 1.1 μM−1 s−1[1]

Literature-Reported Treatment Conditions

Treatment concentration
Variable triphosphate concentrations; Figure 3 spans 20–200 μM (−)FTC-TP
Method
Single-turnover incorporation kinetics at 37°C
Reported limits
No single fixed dose or exposure duration; Table 1 replicate count not specified.
Methods and source locations

Compound reported in the paper: Emtricitabine 5′-triphosphate; Compound label in the paper: (−)FTC-TP

Active-metabolite host-enzyme selectivity; no claim of zero mitochondrial toxicity.

Table 1 and footnotes; Results preceding Table 1; Figure 3; Methods: Reagents and rapid chemical quenching

Maximum observed (−)FTC-TP incorporation rate: Estimate from fastest observed incorporation rate — Table 1: (−)FTC-TP row; footnote a; Results preceding Table 1

Incorporation efficiencies of FTC enantiomers: Reported kinetic specificity constants — Table 1: FTC enantiomer rows

Emtricitabine metabolite accumulation in lymphoid endothelial cells

Cell-based study · Uninfected primary human lymph-node-derived lymphoid endothelial cells; four independent biological replicates [2]

FTC-TP accumulated in cells, but emtricitabine ranked in the low-bioavailability tertile of the tested panel. The ratio uses intracellular metabolite and extracellular parent drug.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular FTC-TP normalized to extracellular FTC concentrationBioavailability tertile Low (<33rd percentile among the tested ARVs)[2]

Literature-Reported Treatment Conditions

Treatment concentration
2000 ng/mL emtricitabine
Exposure duration
72 h
Method
Separate drug exposure; LC-MS/MS quantitation of cell-associated FTC-TP
Reported limits
Cell-treatment vehicle and detailed viability controls were not established from retrieved main text; supplement not retrieved.
Methods and source locations

Compound reported in the paper: Emtricitabine; Compound label in the paper: FTC; measured metabolite FTC-TP

Parent-drug uptake/metabolism model; no infection assay or antiviral potency endpoint.

Methods: ARVs, cell-associated quantitation, Sample size and Data analyses; Results: ARV bioavailability in HLECs; Figure 1

Intracellular FTC-TP normalized to extracellular FTC concentration: LC-MS/MS; ICC/Cmax ratio — Results: ARV bioavailability in HLECs; Figure 1b and caption

Emtricitabine In Vivo Studies

In healthy BALB/c mice receiving emtricitabine with efavirenz and dolutegravir, FTC-TP exposure varied across tissues, with the lowest tissue/plasma ratio in brain. The experiment measured distribution after combination dosing and does not demonstrate emtricitabine monotherapy efficacy. [2]

Tissue metabolite distribution during combination dosing in healthy mice

Animal study · Healthy male BALB/c mice, 8–10 weeks old; n = 6 [2]

After combination dosing, tissue FTC-TP/plasma FTC ratios differed across lymph nodes, gut and brain. These are metabolite/parent ratios at one sampling time, not absolute bioavailability or antiviral efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tissue FTC-TP concentration divided by plasma FTC concentrationTissue/plasma ratio LN: 0.0026; gut: 0.00082; brain ratio lower than both (exact value not adopted)[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
3 consecutive days; sample 4 h after dose 3
Vehicle
DMSO/PEG400/propylene glycol/ethanol/Kolliphor EL/1× PBS (8/25/15/10/7/35% v/v)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
EFV/DTG/FTC combination
Emtricitabine 30 mg/kg; efavirenz 50 mg/kg; dolutegravir 10 mg/kg
No untreated or FTC-only PK arm described; tissue values normalized to paired plasma concentrationFTC-TP/plasma FTC ratios: LN 0.0026; gut 0.00082; brain lower than both (exact value not adopted)[2]
EFV/DTG/FTC combination
Model: Six healthy male BALB/c mice, 8–10 weeks
Reported limits: Only one sampling time; combination design does not isolate monotherapy pharmacokinetics.
Methods and source locations

Compound reported in the paper: Emtricitabine; Compound label in the paper: FTC; measured metabolite FTC-TP

Combination pharmacokinetics in healthy animals; no single-agent efficacy inference.

Methods: Experimental animals, Study design, Sample size and Data analyses; Results: ARV bioavailability in mouse LNs, gut and brain tissues; Figure 2

Tissue FTC-TP concentration divided by plasma FTC concentration: LC-MS/MS; single time-point tissue/plasma comparison — Results: ARV bioavailability in mouse LNs, gut and brain tissues; Figure 2 caption defines analytes

EFV/DTG/FTC combination · Methods: Study design and Sample size; Results: mouse tissue bioavailability; Figure 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 143491-57-0
Applications NRT inhibitor
Formula C8H10FN3O3S
Molecular Weight 247.3
Synonyms Emtriva
SMILES
C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 47 mg/mL (190.08 mM)
Water 47 mg/mL (190.08 mM)
Ethanol 9 mg/mL (36.4 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Emtricitabine Research References

  1. [1] Joy Y Feng, Eisuke Murakami, Suzana M Zorca, et al. Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase Antimicrobial Agents and Chemotherapy (2004). PMID: 15047533 DOI: 10.1128/AAC.48.4.1300-1306.2004 Source material
  2. [2] Shetty Ravi Dyavar, Nagsen Gautam, Anthony T Podany, et al. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice Journal of Antimicrobial Chemotherapy (2019). PMID: 31335938 DOI: 10.1093/jac/dkz273 Source material

Added to your cart

View Cart Checkout
Loading...